Abstract
Tryptases comprise a group of trypsin-like serine proteases that are highly and selectively expressed in mast cells and to a lesser extent in basophils. Among them interest has been focused on tryptase β, primarily because it was the first tryptase identified and because it is the predominant protease and protein component of mast cells. Subsequent studies have provided convincing evidence that tryptase β is not only a clinically useful marker of mast cells and their activation but that it contributes to the pathogenesis of allergic inflammatory disorders, most notably asthma. The pathogenetic relevance together with the apparent lack of overt physiological functions has caused considerable interest in β-tryptase as a potential therapeutic target. Meanwhile diverse tryptase inhibitors have been synthesized whose design in part was fostered by the structural analysis of the enzymatically active β tryptase tetramer. Various compounds have been studied both in animal models and in man, providing proof of principle that tryptase inhibitors have therapeutic potential in asthma. Here we review the rationale to develop tryptase inhibitors and the approaches pursued, and also try to pinpoint some of the problems that hamper the development of clinically applicable drugs.
Keywords: Mast cells, tryptases, tryptase inhibitors, allergic inflammation, asthma
Current Pharmaceutical Design
Title: Mast Cell Tryptase β as a Target in Allergic Inflammation: An Evolving Story
Volume: 13 Issue: 3
Author(s): C. P. Sommerhoff and N. Schaschke
Affiliation:
Keywords: Mast cells, tryptases, tryptase inhibitors, allergic inflammation, asthma
Abstract: Tryptases comprise a group of trypsin-like serine proteases that are highly and selectively expressed in mast cells and to a lesser extent in basophils. Among them interest has been focused on tryptase β, primarily because it was the first tryptase identified and because it is the predominant protease and protein component of mast cells. Subsequent studies have provided convincing evidence that tryptase β is not only a clinically useful marker of mast cells and their activation but that it contributes to the pathogenesis of allergic inflammatory disorders, most notably asthma. The pathogenetic relevance together with the apparent lack of overt physiological functions has caused considerable interest in β-tryptase as a potential therapeutic target. Meanwhile diverse tryptase inhibitors have been synthesized whose design in part was fostered by the structural analysis of the enzymatically active β tryptase tetramer. Various compounds have been studied both in animal models and in man, providing proof of principle that tryptase inhibitors have therapeutic potential in asthma. Here we review the rationale to develop tryptase inhibitors and the approaches pursued, and also try to pinpoint some of the problems that hamper the development of clinically applicable drugs.
Export Options
About this article
Cite this article as:
Sommerhoff P. C. and Schaschke N., Mast Cell Tryptase β as a Target in Allergic Inflammation: An Evolving Story, Current Pharmaceutical Design 2007; 13 (3) . https://dx.doi.org/10.2174/138161207779313579
DOI https://dx.doi.org/10.2174/138161207779313579 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protection by Nigella Sativa [Black Seed] against Hyperhomocysteinemia in Rats
Vascular Disease Prevention (Discontinued) New Developments in Inhaled Antibiotics for the Treatment of Pseudomonas aeruginosa
Current Pharmaceutical Design Carbon Monoxide and Iron Modulate Plasmatic Coagulation in Alzheimer’s disease
Current Neurovascular Research Gastrin-Releasing Peptide Receptor as a Molecular Target for Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Preface
Current Pharmaceutical Design Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Recent Patents on Anti-Cancer Drug Discovery Advances in Design and Development of Inhibitors of Nitric Oxide Synthases
Current Enzyme Inhibition Biomarker-Detection Technologies for Comprehensive Medical Diagnosis During Deep-Space Missions
Recent Patents on Space Technology The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Viral Bronchiolitis and Asthma Development: Lessons from Longitudinal Studies
Current Respiratory Medicine Reviews A Common Molecular Motif Characterizes Extracellular Allosteric Enhancers of GPCR Aminergic Receptors and Suggests Enhancer Mechanism of Action
Current Medicinal Chemistry Use of Natural Compounds as a Potential Therapeutic Agent Against COVID-19
Current Pharmaceutical Design Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Current Drug Safety The Patents on Glucocorticosteroids and Selected New Therapies for the Management of Asthma in Children
Recent Patents on Inflammation & Allergy Drug Discovery Cationic Surfactants and Lipids as Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma
Current Drug Safety Pneumopericardium after Foreign Body Aspiration: A Case Report
New Emirates Medical Journal Use of Phase III Slope of Volumetric Capnography in Outpatient Clinical Practice: A Descriptive Analysis
Current Respiratory Medicine Reviews Lyn Regulates Cytotoxicity in Respiratory Epithelial Cells Challenged by Cigarette Smoke Extracts
Current Molecular Medicine